New Research Of Children's Autism.
An speculative drug for autism did not pick up levels of lethargy and social withdrawal in children who took it, but it did show some other benefits, a budding study finds in May 2013. Children on arbaclofen did improve on an overall measure of autism starkness when compared to kids taking an inactive placebo, said lead researcher Dr Jeremy Veenstra-VanderWeele, an associate professor of psychiatry, pediatrics and pharmacology at Vanderbilt University. He is to present the findings Thursday at the International Meeting for Autism Research (IMFAR) in Spain.
One of 88 children in the United States is now diagnosed with an autism spectrum disorder, the parasol call for complex brain phenomenon disorders marked by problems in social interaction and communication. Veenstra-VanderWeele focused on evaluating the public improvement with the drug because earlier research had suggested it could help. However, one of the earlier studies did not analogize the drug to a placebo, but simply measured improvement in those who took the drug.
In the new study, Veenstra-VanderWeele and his line-up assigned 150 people with autism, aged 5 to 21, to take the cure-all or a placebo, without knowing which group they were in, for eight weeks. The participants had been diagnosed with autistic disorder, Asperger's syndrome or another interconnected condition known as pervasive developmental disorder. In all, 130 finished the study.
Saturday, 18 January 2020
Some Types Of Antidepressants Increase The Risk Of Miscarriage
Some Types Of Antidepressants Increase The Risk Of Miscarriage.
Women who engage a steady class of antidepressants during pregnancy may increase their risk of having a frustration by 68 percent, Canadian researchers report. Antidepressant use is common during pregnancy, with up to 3,7 percent of women taking the drugs during the essential trimester. Stopping treatment can lead to a return of depression and other symptoms, and earlier studies of the medications' effects on the fetus have been small and had contradictory results.
But the Canadian case-control mull over on more than 5000 women found that by controlling for other factors associated with miscarriage, taking antidepressants known as eclectic serotonin reuptake inhibitors (SSRIs) during pregnancy led to an increased risk of miscarriage. Up to 20 percent - or one baggage out of five - will suffer a miscarriage for various reasons during pregnancy. But the inspect results suggest that SSRIs as a class increase that risk, according to lead researcher Anick Berard, an confederate professor at the University of Montreal.
The results "are highly robust given the big-hearted number of users studied". In addition the study makes clear that the drugs, rather than the mothers' despondency and anxiety, are associated with an increased risk for miscarriage.
However, the author of an accompanying editorial famed that the finding is far from definitive. "This is an association, not a cause," said Adrienne Einarson, assistant headman of the Motherisk Program at the Hospital for Sick Children in Toronto. "We still don't know if it's the impression or the drug".
Also, the risk uncovered by the study is a very small one. "Less than twice as many women had miscarriages in the classify with antidepressants as those who did not take antidepressants. It's a very small risk indeed, and it's not a common sense to stop taking an antidepressant if you need it".
Women who engage a steady class of antidepressants during pregnancy may increase their risk of having a frustration by 68 percent, Canadian researchers report. Antidepressant use is common during pregnancy, with up to 3,7 percent of women taking the drugs during the essential trimester. Stopping treatment can lead to a return of depression and other symptoms, and earlier studies of the medications' effects on the fetus have been small and had contradictory results.
But the Canadian case-control mull over on more than 5000 women found that by controlling for other factors associated with miscarriage, taking antidepressants known as eclectic serotonin reuptake inhibitors (SSRIs) during pregnancy led to an increased risk of miscarriage. Up to 20 percent - or one baggage out of five - will suffer a miscarriage for various reasons during pregnancy. But the inspect results suggest that SSRIs as a class increase that risk, according to lead researcher Anick Berard, an confederate professor at the University of Montreal.
The results "are highly robust given the big-hearted number of users studied". In addition the study makes clear that the drugs, rather than the mothers' despondency and anxiety, are associated with an increased risk for miscarriage.
However, the author of an accompanying editorial famed that the finding is far from definitive. "This is an association, not a cause," said Adrienne Einarson, assistant headman of the Motherisk Program at the Hospital for Sick Children in Toronto. "We still don't know if it's the impression or the drug".
Also, the risk uncovered by the study is a very small one. "Less than twice as many women had miscarriages in the classify with antidepressants as those who did not take antidepressants. It's a very small risk indeed, and it's not a common sense to stop taking an antidepressant if you need it".
Friday, 17 January 2020
Doctors Recommend That Pregnant Women Have To Make A Flu Shot
Doctors Recommend That Pregnant Women Have To Make A Flu Shot.
Pregnant women were urged to get a flu launch during the 2009 H1N1 pandemic, and further display supports that advice. Norwegian researchers have found that vaccination in pregnancy was safe for origin and child, and that fetal deaths were more common among unvaccinated moms-to-be. Influenza is a serious intimation to a pregnant woman and her unborn child, said Dr Camilla Stoltenberg, director vague of the Norwegian Institute of Public Health in Oslo, lead researcher of the new study. "Our look at indicates that influenza during pregnancy was a risk factor for stillbirth during the pandemic in 2009".
And "We judge no indication that pandemic vaccination in the second or third trimester increased the risk of stillbirth". With this year's flu pummeling many folk across the United States, experts reveal the best way a pregnant woman can protect her unborn baby from flu complications is by getting a flu shot. "In adding to protecting the mother against severe influenza, the vaccine protects the fetus and the lassie in the first months after birth, when the child is too young to be vaccinated".
The US Centers for Disease Control and Prevention recommends a flu spot for everyone over 6 months of age. Besides replete women, the CDC says the elderly and anyone with a chronic condition such as asthma or diabetes are especially vulnerable to infection.
For the study, published Jan 16, 2013 in the New England Journal of Medicine, Stoltenberg's crew cool data on more than 117000 women in Norway who were pregnant between 2009 and 2010 - the take of the H1N1 pandemic. The investigators found the rate of fetal deaths was almost five per 1000 women.
Pregnant women were urged to get a flu launch during the 2009 H1N1 pandemic, and further display supports that advice. Norwegian researchers have found that vaccination in pregnancy was safe for origin and child, and that fetal deaths were more common among unvaccinated moms-to-be. Influenza is a serious intimation to a pregnant woman and her unborn child, said Dr Camilla Stoltenberg, director vague of the Norwegian Institute of Public Health in Oslo, lead researcher of the new study. "Our look at indicates that influenza during pregnancy was a risk factor for stillbirth during the pandemic in 2009".
And "We judge no indication that pandemic vaccination in the second or third trimester increased the risk of stillbirth". With this year's flu pummeling many folk across the United States, experts reveal the best way a pregnant woman can protect her unborn baby from flu complications is by getting a flu shot. "In adding to protecting the mother against severe influenza, the vaccine protects the fetus and the lassie in the first months after birth, when the child is too young to be vaccinated".
The US Centers for Disease Control and Prevention recommends a flu spot for everyone over 6 months of age. Besides replete women, the CDC says the elderly and anyone with a chronic condition such as asthma or diabetes are especially vulnerable to infection.
For the study, published Jan 16, 2013 in the New England Journal of Medicine, Stoltenberg's crew cool data on more than 117000 women in Norway who were pregnant between 2009 and 2010 - the take of the H1N1 pandemic. The investigators found the rate of fetal deaths was almost five per 1000 women.
Experts Urge Parents To Buy Kids Sunglasses Against Ultraviolet Radiation
Experts Urge Parents To Buy Kids Sunglasses Against Ultraviolet Radiation.
With May designated as UV awareness month, experts are occupation on parents to give particular heed to the safety of their children's eyes this summer. Although eye keeping is a concern for people of all ages, Prevent Blindness America, the nation's oldest eye healthiness and safety organization, warns that children are particularly vulnerable to the harmful ultraviolet A and B (UVA and UVB) price that can accompany sun exposure. For one, children in the main spend more time in the sun, the group noted.
In addition, the organization highlights the American Optometric Association's cautionary judgement that the lenses of young eyes are more transparent than that of adults, risking retinal location to a greater degree of short wavelength light. "We need to remember to take care of our eyes from UV every day of the year," Hugh R Parry, president and CEO of Prevent Blindness America, said in a communication release. "UV rays reflecting off the water, sand, pavement and even snow are uncommonly dangerous. We can encourage our children to wear the proper ogle protection by leading by example".
UV exposure has been linked to the onset of cataracts, macular degeneration and a major array of eye health issues, the experts noted. Prevent Blindness America advises that each and every one who goes out in the sun should wear sunglasses that block out 99 percent to 100 percent of both UVA and UVB dispersal - noting that sunglasses without such protection can actually cause the pupils to dilate, thereby doing more hurt than good. A wide-brimmed hat or cap also offers some measure of eye protection, the batch suggested.
With specific respect to children, Prevent Blindness America further encourages parents to make safe that sunglasses fit their child's face properly and shields the sun's rays from all directions. The league points out that wrap-around sunglasses might be optimal in the later regard, because they additionally defend the skin immediately surrounding a child's eyes. Sunglasses, they note, should always be composed of impact-resistant polycarbonates, rather than glass, and should be scratch-free.
With May designated as UV awareness month, experts are occupation on parents to give particular heed to the safety of their children's eyes this summer. Although eye keeping is a concern for people of all ages, Prevent Blindness America, the nation's oldest eye healthiness and safety organization, warns that children are particularly vulnerable to the harmful ultraviolet A and B (UVA and UVB) price that can accompany sun exposure. For one, children in the main spend more time in the sun, the group noted.
In addition, the organization highlights the American Optometric Association's cautionary judgement that the lenses of young eyes are more transparent than that of adults, risking retinal location to a greater degree of short wavelength light. "We need to remember to take care of our eyes from UV every day of the year," Hugh R Parry, president and CEO of Prevent Blindness America, said in a communication release. "UV rays reflecting off the water, sand, pavement and even snow are uncommonly dangerous. We can encourage our children to wear the proper ogle protection by leading by example".
UV exposure has been linked to the onset of cataracts, macular degeneration and a major array of eye health issues, the experts noted. Prevent Blindness America advises that each and every one who goes out in the sun should wear sunglasses that block out 99 percent to 100 percent of both UVA and UVB dispersal - noting that sunglasses without such protection can actually cause the pupils to dilate, thereby doing more hurt than good. A wide-brimmed hat or cap also offers some measure of eye protection, the batch suggested.
With specific respect to children, Prevent Blindness America further encourages parents to make safe that sunglasses fit their child's face properly and shields the sun's rays from all directions. The league points out that wrap-around sunglasses might be optimal in the later regard, because they additionally defend the skin immediately surrounding a child's eyes. Sunglasses, they note, should always be composed of impact-resistant polycarbonates, rather than glass, and should be scratch-free.
Another Genetic Cause Of Alzheimer's Disease
Another Genetic Cause Of Alzheimer's Disease.
Researchers have discovered that the variation of a gene associated with beginning onset Alzheimer's may block a key recycling process demanded for brain cell survival - a finding that points the way to possible treatment for the disease. When it's working properly, this gene - called presenilin 1 (PS1) - performs a vital house-cleaning utility by helping brain cells digest unwanted, damaged and potentially toxic proteins.
But in its mutated form, the gene fails to supporter cells recycle these capability toxins, suggesting an explanation for the damage to the brain characteristic of Alzheimer's disease. "We hold we have identified the principal mechanism by which mutations of PS1 cause the most common genetic appear of Alzheimer's disease," study co-author Dr Ralph A Nixon, professor in the departments of psychiatry and chamber biology as well as director of NYU's Center of Excellence on Brain Aging and the Silberstein Alzheimer's Institute, said in a university rumour release.
And "Presently, no effective treatment exists to either unproductive or prevent the progression of Alzheimer's disease," added Nixon, also director of the Center for Dementia Research at the Nathan S Kline Institute for Psychiatric Research in New York City. "This unearthing has the the of identifying such a treatment".
Researchers have discovered that the variation of a gene associated with beginning onset Alzheimer's may block a key recycling process demanded for brain cell survival - a finding that points the way to possible treatment for the disease. When it's working properly, this gene - called presenilin 1 (PS1) - performs a vital house-cleaning utility by helping brain cells digest unwanted, damaged and potentially toxic proteins.
But in its mutated form, the gene fails to supporter cells recycle these capability toxins, suggesting an explanation for the damage to the brain characteristic of Alzheimer's disease. "We hold we have identified the principal mechanism by which mutations of PS1 cause the most common genetic appear of Alzheimer's disease," study co-author Dr Ralph A Nixon, professor in the departments of psychiatry and chamber biology as well as director of NYU's Center of Excellence on Brain Aging and the Silberstein Alzheimer's Institute, said in a university rumour release.
And "Presently, no effective treatment exists to either unproductive or prevent the progression of Alzheimer's disease," added Nixon, also director of the Center for Dementia Research at the Nathan S Kline Institute for Psychiatric Research in New York City. "This unearthing has the the of identifying such a treatment".
Surgery For Fibromyalgia Treatment
Surgery For Fibromyalgia Treatment.
An implanted cognizance that zaps the nerves at the nape of the neck - shown in operation in treating some people with migraines - may also help informality the ache of fibromyalgia, an ailment that causes widespread body pain and tenderness. A Belgian scientist treated reduced numbers of fibromyalgia patients with "occipital nerve stimulation," which rouses the occipital nerves just below the skin at the back of the neck using an implanted device. Dr Mark Plazier found that misery scores dropped for 20 of 25 patients using this device over six months and their quality of sustenance improved significantly.
And "There are only a few treatment options for fibromyalgia right now and the response to treatment is far from 100 percent, which implies there are a lot of patients still looking for daily to get a better life. This treatment might be an excellent privilege for them," said Plazier, a neurosurgeon at University Hospital Antwerp. But, "it is thorny to determine the impact of these findings on fibromyalgia patients, since larger trials are necessary".
Plazier is to present his digging this week at a meeting of the International Neuromodulation Society, in Berlin. Neuromodulation is a group of therapies that use medical devices to aid symptoms or restore abilities by altering nerve system function.
Research presented at systematic conferences has not typically been peer-reviewed or published and is considered preliminary.
An implanted cognizance that zaps the nerves at the nape of the neck - shown in operation in treating some people with migraines - may also help informality the ache of fibromyalgia, an ailment that causes widespread body pain and tenderness. A Belgian scientist treated reduced numbers of fibromyalgia patients with "occipital nerve stimulation," which rouses the occipital nerves just below the skin at the back of the neck using an implanted device. Dr Mark Plazier found that misery scores dropped for 20 of 25 patients using this device over six months and their quality of sustenance improved significantly.
And "There are only a few treatment options for fibromyalgia right now and the response to treatment is far from 100 percent, which implies there are a lot of patients still looking for daily to get a better life. This treatment might be an excellent privilege for them," said Plazier, a neurosurgeon at University Hospital Antwerp. But, "it is thorny to determine the impact of these findings on fibromyalgia patients, since larger trials are necessary".
Plazier is to present his digging this week at a meeting of the International Neuromodulation Society, in Berlin. Neuromodulation is a group of therapies that use medical devices to aid symptoms or restore abilities by altering nerve system function.
Research presented at systematic conferences has not typically been peer-reviewed or published and is considered preliminary.
Vitamin E Fights Against Diseases
Vitamin E Fights Against Diseases.
There might be some credible news in the wrangle against Alzheimer's disease: A new study suggests that a large daily dose of vitamin E might labourer slow progression of the memory-robbing illness. Alzheimer's patients given a "pharmacological" portion of vitamin E experienced slower declines in thinking and memory and required less caregiver metre than those taking a placebo, said Dr Maurice Dysken, lead author of a new study published Dec 31, 2013 in the Journal of the American Medical Association. "We found vitamin E significantly slowed the have a claim to of advance versus placebo," said Dysken, who is with the Geriatric Research Education and Clinical Center of the Minneapolis VA Health Care System.
Experts stressed, however, that vitamin E does not seem to wrestle the underlying cause of Alzheimer's and is in no nature a cure. The study involved more than 600 patients at 14 VA medical centers with kind to moderate Alzheimer's. Researchers separation the group into quarters, with each receiving a different therapy. One-quarter received a daily dose of 2000 supranational units (IU) of alpha tocopherol, a form of vitamin E That's a to some degree large dose; by comparison, a daily multivitamin contains only about 100 IUs of vitamin E.
The other sets of patients were given the Alzheimer's medication memantine, a syndication of vitamin E and memantine, or a placebo. People who took vitamin E merely experienced a 19 percent reduction in their annual estimate of decline compared to a placebo during the study's average 2,3 years of follow-up, the researchers said. In reasonable terms, this means the vitamin E group enjoyed a more than six-month hold up in the progression of Alzheimer's, the researchers said.
This delay could mean a lot to patients, the researchers said, noting that the settle experienced by the placebo group could translate into the complete loss of the ability to dress or bathe independently. The researchers also found that ancestors in the vitamin E group needed about two fewer hours of tribulation each day. Neither memantine nor the combination of vitamin E plus memantine showed clinical benefits in this trial. Therapy with vitamin E also appears to be safe, with no increased jeopardize of malady or death, the researchers found.
There might be some credible news in the wrangle against Alzheimer's disease: A new study suggests that a large daily dose of vitamin E might labourer slow progression of the memory-robbing illness. Alzheimer's patients given a "pharmacological" portion of vitamin E experienced slower declines in thinking and memory and required less caregiver metre than those taking a placebo, said Dr Maurice Dysken, lead author of a new study published Dec 31, 2013 in the Journal of the American Medical Association. "We found vitamin E significantly slowed the have a claim to of advance versus placebo," said Dysken, who is with the Geriatric Research Education and Clinical Center of the Minneapolis VA Health Care System.
Experts stressed, however, that vitamin E does not seem to wrestle the underlying cause of Alzheimer's and is in no nature a cure. The study involved more than 600 patients at 14 VA medical centers with kind to moderate Alzheimer's. Researchers separation the group into quarters, with each receiving a different therapy. One-quarter received a daily dose of 2000 supranational units (IU) of alpha tocopherol, a form of vitamin E That's a to some degree large dose; by comparison, a daily multivitamin contains only about 100 IUs of vitamin E.
The other sets of patients were given the Alzheimer's medication memantine, a syndication of vitamin E and memantine, or a placebo. People who took vitamin E merely experienced a 19 percent reduction in their annual estimate of decline compared to a placebo during the study's average 2,3 years of follow-up, the researchers said. In reasonable terms, this means the vitamin E group enjoyed a more than six-month hold up in the progression of Alzheimer's, the researchers said.
This delay could mean a lot to patients, the researchers said, noting that the settle experienced by the placebo group could translate into the complete loss of the ability to dress or bathe independently. The researchers also found that ancestors in the vitamin E group needed about two fewer hours of tribulation each day. Neither memantine nor the combination of vitamin E plus memantine showed clinical benefits in this trial. Therapy with vitamin E also appears to be safe, with no increased jeopardize of malady or death, the researchers found.
Parkinson's Disease Affects Humanity
Parkinson's Disease Affects Humanity.
A long-term use program may help calm depression in people with Parkinson's disease, according to a new, small study Dec 2013. Researchers looked at 31 Parkinson's patients who were randomly assigned to an "early start" heap that did an put to use program for 48 weeks or a "late start" group that worked out for 24 weeks. The program included three one-hour cardiovascular and denial training workouts a week.
Depression symptoms improved much more amid the patients in the 48-week group than among those in the 24-week group. This is vital because mood is often more debilitating than movement problems for Parkinson's patients, said study leader Dr Ariane Park, a action disorder neurologist at Ohio State University's Wexner Medical Center. The examination was published online recently in the journal Parkinsonism andamp; Related Disorders.
A long-term use program may help calm depression in people with Parkinson's disease, according to a new, small study Dec 2013. Researchers looked at 31 Parkinson's patients who were randomly assigned to an "early start" heap that did an put to use program for 48 weeks or a "late start" group that worked out for 24 weeks. The program included three one-hour cardiovascular and denial training workouts a week.
Depression symptoms improved much more amid the patients in the 48-week group than among those in the 24-week group. This is vital because mood is often more debilitating than movement problems for Parkinson's patients, said study leader Dr Ariane Park, a action disorder neurologist at Ohio State University's Wexner Medical Center. The examination was published online recently in the journal Parkinsonism andamp; Related Disorders.
Thursday, 16 January 2020
Contrave, A New Weight Loss Pill Combines Anti-Addiction Medication And An Antidepressant
Contrave, A New Weight Loss Pill Combines Anti-Addiction Medication And An Antidepressant.
An dexterous monitory panel recommended on Tuesday that Contrave, a unknown weight-loss pill that combines an antidepressant with an anti-addiction medication, be approved by the US Food and Drug Administration. The 13-7 preference in favor of Contrave came amid agency concerns that the numb might raise blood pressure in some patients and increase the risk of heart attacks and strokes centre of some users, according to the Associated Press. But panelists voted 11-8 earlier in the heyday that those potential health risks could be studied after Contrave was approved.
The FDA does not have to follow the advice of its advisory committees, but it typically does. The mechanism is expected to make a decision on Contrave by Jan 31, 2011, the wire utilization reported. Contrave is manufactured by Orexigen Therapeutics Inc. In October, the FDA voted against approving two other weight-loss drugs, Arena Pharmaceuticals' lorcaserin and Vivus' Qnexa, because of cover concerns, according to the AP. Last July, a muse about funded by Orexigen and published in The Lancet found that Contrave helped users pour pounds when taken along with a well diet and exercise.
People who took the drug for more than a year lost an average of 5 percent or more of body weight, depending on the dosage used, the team said. However, the regimen did come with side effects, and about half of scan participants dropped out before completing a year of treatment. Contrave is combination of two familiar drugs, naltrexone (Revia, used to fight addictions) and the antidepressant bupropion (known by a host of names, including Wellbutrin).
The drug appears to boost weight loss by changing the workings of the body's essential nervous system, the researchers said. The study enrolled men (15 percent) and women (85 percent) from around the country, ranging in epoch from 18 to 65. They were all either pudgy or overweightm, with high blood fat levels or high blood pressure.
An dexterous monitory panel recommended on Tuesday that Contrave, a unknown weight-loss pill that combines an antidepressant with an anti-addiction medication, be approved by the US Food and Drug Administration. The 13-7 preference in favor of Contrave came amid agency concerns that the numb might raise blood pressure in some patients and increase the risk of heart attacks and strokes centre of some users, according to the Associated Press. But panelists voted 11-8 earlier in the heyday that those potential health risks could be studied after Contrave was approved.
The FDA does not have to follow the advice of its advisory committees, but it typically does. The mechanism is expected to make a decision on Contrave by Jan 31, 2011, the wire utilization reported. Contrave is manufactured by Orexigen Therapeutics Inc. In October, the FDA voted against approving two other weight-loss drugs, Arena Pharmaceuticals' lorcaserin and Vivus' Qnexa, because of cover concerns, according to the AP. Last July, a muse about funded by Orexigen and published in The Lancet found that Contrave helped users pour pounds when taken along with a well diet and exercise.
People who took the drug for more than a year lost an average of 5 percent or more of body weight, depending on the dosage used, the team said. However, the regimen did come with side effects, and about half of scan participants dropped out before completing a year of treatment. Contrave is combination of two familiar drugs, naltrexone (Revia, used to fight addictions) and the antidepressant bupropion (known by a host of names, including Wellbutrin).
The drug appears to boost weight loss by changing the workings of the body's essential nervous system, the researchers said. The study enrolled men (15 percent) and women (85 percent) from around the country, ranging in epoch from 18 to 65. They were all either pudgy or overweightm, with high blood fat levels or high blood pressure.
Treatment Of Heart Attack With The Help Of Stem Cells From Belly Fat
Treatment Of Heart Attack With The Help Of Stem Cells From Belly Fat.
Stem cells enchanted from the belly unctuous of 10 love attack patients managed to improve several measures of heart function, Dutch researchers report. This is the premier time this type of therapy has been used in humans, said the scientists, who presented their findings Tuesday at the American Heart Association's annual gathering in Chicago. But the improvements, though to some degree dramatic in this small group of patients, were not statistically significant, probably due to the minimal number of participants in the study.
And another expert urged caution when interpreting the results. "The opener issue is whether a treatment makes us live longer or feel better," said Dr Jeffrey S Borer, rocking-chair of the department of medicine and of cardiovascular medicine at the State University of New York (SUNY) Downstate Medical Center in New York City. This workroom only looked at "surrogates," import measures of heart function that might predict better future health in the patient.
So "This cannot be interpreted as if they instantly represent positive clinical outcomes. These certainly are reassuring stem cell data, but there's a great deal more to do before it is possible to know whether this is a viable therapy".
Another caveat: All the patients in this experimental were white Europeans. The study authors believe the results could be extrapolated to much of the US population, but not unavoidably to people who aren't white. Fat tissue yields many more stem-post cells than bone marrow (which has been studied before) and is much easier to access.
In bone marrow, 40 cubic centimeters (cc) typically revenue about 25000 stem cells, which is "not nearly enough to treat men and women with," said study author Dr Eric Duckers, head of the Molecular Cardiology Laboratory at Thoraxcenter, Erasmus University Medical Center in Rotterdam. To get enough cells to exert oneself with, those arrest cells would have to be cultured, a process that can take six to eight weeks.
Stem cells enchanted from the belly unctuous of 10 love attack patients managed to improve several measures of heart function, Dutch researchers report. This is the premier time this type of therapy has been used in humans, said the scientists, who presented their findings Tuesday at the American Heart Association's annual gathering in Chicago. But the improvements, though to some degree dramatic in this small group of patients, were not statistically significant, probably due to the minimal number of participants in the study.
And another expert urged caution when interpreting the results. "The opener issue is whether a treatment makes us live longer or feel better," said Dr Jeffrey S Borer, rocking-chair of the department of medicine and of cardiovascular medicine at the State University of New York (SUNY) Downstate Medical Center in New York City. This workroom only looked at "surrogates," import measures of heart function that might predict better future health in the patient.
So "This cannot be interpreted as if they instantly represent positive clinical outcomes. These certainly are reassuring stem cell data, but there's a great deal more to do before it is possible to know whether this is a viable therapy".
Another caveat: All the patients in this experimental were white Europeans. The study authors believe the results could be extrapolated to much of the US population, but not unavoidably to people who aren't white. Fat tissue yields many more stem-post cells than bone marrow (which has been studied before) and is much easier to access.
In bone marrow, 40 cubic centimeters (cc) typically revenue about 25000 stem cells, which is "not nearly enough to treat men and women with," said study author Dr Eric Duckers, head of the Molecular Cardiology Laboratory at Thoraxcenter, Erasmus University Medical Center in Rotterdam. To get enough cells to exert oneself with, those arrest cells would have to be cultured, a process that can take six to eight weeks.
Subscribe to:
Posts (Atom)